Andreessen Horowitz and Eli Lilly Launch $500M Biotech Ecosystem Fund

Andreessen Horowitz (a16z) Bio + Health and Eli Lilly and Company have joined forces to create the Biotech Ecosystem Venture Fund, a new venture capital initiative aimed at driving healthcare transformation through investments in therapeutic platforms and technology companies.

The fund, managed by a16z Bio + Health, will deploy up to $500 million across various stages of company development, from creation to growth. Its focus encompasses advancing new medicine development, enabling novel modality platforms, and scaling emerging health technologies.

Dr. Vineeta Agarwala, general partner at a16z Bio + Health, emphasized the fund's mission: "The Biotech Ecosystem Venture Fund seeks to enable visionary founders to create enduring solutions in biotech and healthcare. Combining our strengths as organizations will empower founders with not only the venture backing needed to advance groundbreaking technologies, but also the resources needed to strategically select the most promising application areas for these platforms."

The partnership leverages a16z's expertise in sourcing, building, and scaling bio + health companies while utilizing Lilly's extensive life science research and development experience. A key component of this collaboration is access to Lilly's Catalyze360™, a specialized support structure for biotech startups that encompasses Lilly Ventures, Lilly Gateway Labs, and Lilly ExplorR&D.

Nisha Nanda, group vice president at Catalyze360, explained the initiative's significance: "Catalyze360 was created to accelerate the success of emerging biotech startups by providing access to people, tools, capabilities and expertise that is traditionally hard for early-stage companies to reach. With the Biotech Ecosystem Fund, we can further scale our work to empower entrepreneurs as they work to bring transformative therapies to patients faster."

The fund takes a long-term approach to support disruptive companies in realizing the full potential of new biological science, engineering technologies, and AI capabilities. This strategy aligns with both organizations' commitment to fostering an ecosystem of ambitious healthcare entrepreneurs and innovators.

Dr. Agarwala further noted: "The creation of this new fund signifies a shared passion and commitment with Lilly to deliver truly meaningful change in our ability to treat and care for people living with disease.”

Click here for the original news story.